© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 13, 1001-1009,
July 3, 2002
© 2002 Oxford University Press
ARTICLE |
A Randomized Phase IIb Trial of Anethole Dithiolethione in Smokers with Bronchial Dysplasia
Affiliations of authors: S. Lam (Department of Respiratory Medicine), C. MacAulay, M. Guillaud (Department of Cancer Imaging), J. C. le Riche (Department of Pathology), Y. Dyachkova, A. Coldman (Department of Population and Preventive Oncology), British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada; E. Hawk, Division of Cancer Prevention, Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Bethesda, MD; M.-O. Christen, Solvay Pharma, Suresnes, France; A. F. Gazdar, Hamon Center for Therapeutic Oncology Research and Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
Correspondence to: Stephen Lam, M.D., F.R.C.P.C., 2775 Heather St., Vancouver, British Columbia, Canada V5Z 3J5 (e-mail: sclam{at}interchange.ubc.ca).
Background: Results from preclinical studies have suggested that the organosulfur compound anethole dithiolethione (ADT) may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia. Methods: One hundred twelve current and former smokers with a smoking history of at least 30 pack-years and at least one site of bronchial dysplasia identified by an autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive placebo or ADT at 25 mg orally thrice daily for 6 months. Each subject then underwent a follow-up bronchoscopy-directed biopsy. We used changes in histopathologic grade and nuclear morphometry index (MI) as the primary and secondary end point biomarkers, respectively. Chi-square tests with continuity correction were used to compare response rates on a lesion- and person-specific basis between the two study groups. All statistical tests were two-sided. Results: One hundred one subjects had a follow-up bronchoscopy. In the lesion-specific analysis, progression rate of pre-existing dysplastic lesions by two or more grades and/or the appearance of new lesions was statistically significantly lower in the ADT group (8%) than in the placebo group (17%) (P<.001; difference = 9%, 95% confidence interval [CI] = 4% to 15%). In the person-specific analysis, the disease progression rate was statistically significantly lower in the ADT group (32%) than in the placebo group (59%) (P = .013; difference = 27%, 95% CI = 6% to 48%). The two treatment groups did not differ statistically significantly in terms of nuclear MI. Among individuals with an abnormal nuclear MI before treatment (29 in the ADT group and 25 in the placebo group), the progression rate in the ADT group (41%) was substantially lower than that in the placebo group (60%), although the difference was not statistically significant (P = .28; difference = 19%, 95% CI = –11% to 49%). Adverse events were mostly minor gastrointestinal symptoms that resolved with dose reduction or discontinuation of the medication. Conclusion: Our results suggest that, in smokers, ADT is a potentially efficacious chemoprevention agent for lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Kelly, J. Kittelson, W. A. Franklin, T. C. Kennedy, C. E. Klein, R. L. Keith, E. C. Dempsey, M. Lewis, M. K. Jackson, F. R. Hirsch, et al. A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without {alpha} Tocopherol or Observation in Subjects at High Risk for Lung Cancer Cancer Prevention Research, May 1, 2009; 2(5): 440 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Keith Chemoprevention of Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang and R. Munday Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther., November 1, 2008; 7(11): 3470 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lam, B. Standish, C. Baldwin, A. McWilliams, J. leRiche, A. Gazdar, A. I. Vitkin, V. Yang, N. Ikeda, and C. MacAulay In vivo Optical Coherence Tomography Imaging of Preinvasive Bronchial Lesions Clin. Cancer Res., April 1, 2008; 14(7): 2006 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lam, A. McWilliams, J. leRiche, C. MacAulay, L. Wattenberg, and E. Szabo A Phase I Study of myo-Inositol for Lung Cancer Chemoprevention. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1526 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, P. Gao, and V. E. Steele The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model Carcinogenesis, August 1, 2006; 27(8): 1721 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Karuri, Y. Huang, S. Bodreddigari, C. H. Sutter, B. D. Roebuck, T. W. Kensler, and T. R. Sutter 3H-1,2-Dithiole-3-thione Targets Nuclear Factor {kappa}B to Block Expression of Inducible Nitric-Oxide Synthase, Prevents Hypotension, and Improves Survival in Endotoxemic Rats J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, R. Yao, Y. Yan, Y. Wang, Y. Hara, R. A. Lubet, and M. You A Gene Expression Signature that Can Predict Green Tea Exposure and Chemopreventive Efficacy of Lung Cancer in Mice Cancer Res., February 15, 2006; 66(4): 1956 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Hirsch and S. M. Lippman Advances in the Biology of Lung Cancer Chemoprevention J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lam, J. C. leRiche, A. McWilliams, C. MacAulay, Y. Dyachkova, E. Szabo, J. Mayo, R. Schellenberg, A. Coldman, E. Hawk, et al. A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium Clin. Cancer Res., October 1, 2004; 10(19): 6502 - 6511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang and G. B. Gordon A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Winterhalder, F. R. Hirsch, G. K. Kotantoulas, W. A. Franklin, and P. A. Bunn Jr Chemoprevention of lung cancer--from biology to clinical reality Ann. Onc., February 1, 2004; 15(2): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-K. Kwak, N. Wakabayashi, J. L. Greenlaw, M. Yamamoto, and T. W. Kensler Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway Mol. Cell. Biol., December 1, 2003; 23(23): 8786 - 8794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Means-Markwell, R. I. Linnoila, J. Williams, P. A. Janne, F. Kaye, K. O'Neil, and B. E. Johnson Prospective Study of the Airways and Pulmonary Parenchyma of Patients at Risk for a Second Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5915 - 5921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Roebuck, T. J. Curphey, Y. Li, K. J. Baumgartner, S. Bodreddigari, J. Yan, S. J. Gange, T. W. Kensler, and T. R. Sutter Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz Carcinogenesis, December 1, 2003; 24(12): 1919 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-K. Kwak, N. Wakabayashi, K. Itoh, H. Motohashi, M. Yamamoto, and T. W. Kensler Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway. IDENTIFICATION OF NOVEL GENE CLUSTERS FOR CELL SURVIVAL J. Biol. Chem., February 28, 2003; 278(10): 8135 - 8145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sutedja New techniques for early detection of lung cancer Eur. Respir. J., January 1, 2003; 21(39_suppl): 57S - 66s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]
|
|